Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125

被引:10
作者
Berek, JS [1 ]
机构
[1] Univ Calif Los Angeles, Sch Med, Div Gynecol Oncol, Los Angeles, CA 90095 USA
关键词
D O I
10.1006/gyno.2000.5808
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:225 / 226
页数:2
相关论文
共 27 条
[1]   Advanced epithelial ovarian cancer:: 1998 consensus statements [J].
Berek, JS ;
Bertelsen, K ;
du Bois, A ;
Brady, MF ;
Carmichael, J ;
Eisenhauer, EA ;
Gore, M ;
Grenman, S ;
Hamilton, TC ;
Hansen, SW ;
Harper, PG ;
Horvath, G ;
Kaye, SB ;
Lück, HJ ;
Lund, B ;
McGuire, WP ;
Neijt, JP ;
Ozols, RF ;
Parmar, MKB ;
Piccart-Gebhart, MJ ;
van Rijswijk, R ;
Rosenberg, P ;
Rustin, GJS ;
Sessa, C ;
Thigpen, JT ;
Tropé, C ;
Tuxen, MK ;
Vergote, I ;
Vermorken, JB ;
Willemse, PHB .
ANNALS OF ONCOLOGY, 1999, 10 :87-92
[2]  
BEREK JS, 1981, OBSTET GYNECOL, V58, P192
[3]   CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS [J].
BEREK, JS ;
KNAPP, RC ;
MALKASIAN, GD ;
LAVIN, PT ;
WHITNEY, C ;
NILOFF, JM ;
BAST, RC .
OBSTETRICS AND GYNECOLOGY, 1986, 67 (05) :685-689
[4]   INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE [J].
BEREK, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (10) :675-677
[5]   ADJUVANT THERAPY FOR EARLY-STAGE OVARIAN-CANCER [J].
BEREK, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (15) :1076-1078
[6]  
BEREK JS, 1995, CANCER-AM CANCER SOC, V76, P2092, DOI 10.1002/1097-0142(19951115)76:10+<2092::AID-CNCR2820761331>3.0.CO
[7]  
2-T
[8]  
Berek JS, 1996, CANC J, V2, P134
[9]   Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer [J].
Bristow, RE ;
Montz, FJ ;
Lagasse, LD ;
Leuchter, RS ;
Karlan, BY .
GYNECOLOGIC ONCOLOGY, 1999, 72 (03) :278-287
[10]   The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma [J].
Chi, DS ;
Venkatraman, ES ;
Masson, V ;
Hoskins, WJ .
GYNECOLOGIC ONCOLOGY, 2000, 77 (02) :227-231